Last updated: July 27, 2026
Daridorexant Hydrochloride (Quviviq) Clinical Trials Update, Market Analysis, and Patent/Exclusivity Timeline
Daridorexant hydrochloride (brand: Quviviq) is an oral dual orexin receptor antagonist (DORA) for insomnia. Clinical development is concentrated on next-generation indication expansions and long-term safety/tolerability studies following initial Phase 3 programs that supported FDA approval. Commercial projections hinge on (1) durability of efficacy versus competing DORAs and non-DORA hypnotics, (2) payer and formulary uptake, (3) competitive sequencing as generic hypnotics mature, and (4) the speed and scope of any label expansions (eg, specific insomnia subtypes, comorbid populations).
What clinical trials update matters most for daridorexant hydrochloride in 2024–2026?
Featured approvals and late-stage evidence base
- Daridorexant is already approved (FDA) for insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults.
- The core clinical evidence remains the pivotal Phase 3 insomnia program(s), supplemented by longer-term studies used to support chronic dosing claims and tolerability.
What endpoints drive payer and prescriber adoption
Across the insomnia trial landscape, adoption tends to correlate with:
- Onset efficacy (sleep latency) for sleep onset insomnia
- Maintenance efficacy (wake after sleep onset, total sleep time, sleep efficiency) for sleep maintenance insomnia
- Next-day residual effects and next-day functioning scales, including psychomotor performance and somnolence-related patient-reported outcomes
Where new trials typically add value for DARIDOREXANT
For DORAs in market practice, “incremental” trials that influence adoption usually address one or more of:
- Chronic dosing safety over longer horizons
- Subgroups with higher clinical risk, such as older adults or patients with comorbidities
- Specific insomnia phenotypes (sleep maintenance vs sleep onset dominant)
- Head-to-head or pragmatic trials designed for formulary and guideline committees
(No specific new Phase 3 readouts within 2024–2026 are provided in the dataset available to this model in this run, so the update below focuses on the commercially relevant clinical trial classes and their market impact rather than naming trial identifiers that cannot be verified here.)
What is the current commercial status and dosing profile for daridorexant hydrochloride?
Mechanism and competitive positioning
- Class: dual orexin receptor antagonists (DORAs)
- Differentiators versus Z-drugs and benzodiazepines are commonly framed around sleep architecture impact and lower risk of classic benzodiazepine-like sedation next day, though real-world safety and driving impairment outcomes remain adoption levers.
Dosing and practical use
- Oral administration at bedtime
- Dose selection is typically based on clinical factors and tolerability; real-world prescribing patterns often allocate shares between available dose strengths depending on age and side-effect profile.
Commercial adoption drivers
- Formulary placement versus competing DORAs (and versus non-DORA hypnotics) is typically determined by:
- Symptom coverage (onset and maintenance)
- Next-day impairment risk signals
- Clinically meaningful response rates in broad patient populations
- Prior authorization thresholds and quantity limits
- Copay programs and patient support infrastructure
How does daridorexant hydrochloride compare with competing DORAs and non-DORA hypnotics?
Competitive set (market-relevant)
- Other DORAs used for insomnia: commonly includes lemborexant and suvorexant (class comparators frequently used in formulary and switching decisions).
- Non-DORA hypnotics in the same prescribing ecosystem include Z-drugs and short-acting benzodiazepine receptor agonists, plus selected antidepressant-based off-label regimens in some settings.
What tends to matter in switching
- Efficacy for sleep onset and sleep maintenance in the same label label-aligned patient
- Residual sedation and impairment concerns
- Tolerability and discontinuation rates
- Ease of payer authorization and cost-sharing
How the comparison affects share
- Where competitors offer similar efficacy, payer systems often choose based on:
- Lower net price via rebates
- Higher persistence (lower discontinuation)
- Comparable safety in older cohorts
- Local guideline alignment
What patents protect daridorexant hydrochloride and how does patent life affect competition?
Patent estate impact on generics
The competitive timeline for daridorexant is not determined by exclusivity alone. It also depends on:
- Composition of matter coverage
- Formulation and dose-specific patents
- Method-of-use patents aligned with insomnia endpoints
- Orange Book listings that gate ANDA pathways
Exclusivity and approval timing
- Daridorexant has FDA approval and is marketed under a New Molecular Entity exclusivity regime and later patent-linked exclusivity periods where applicable.
- Actual generic timing is driven by patent expiration and any “skinny label” carve-outs enabled by settlement or paragraph IV outcomes.
Key business implication
Even if market exclusivity could allow an initial generic filing, launch can be blocked by:
- Unexpired Orange Book-listed patents
- Litigation outcomes
- Settlement terms that delay launch dates
(This run does not include the patent-by-patent Orange Book/USPTO dataset needed to list specific US patent numbers, expiration dates, and paragraph IV events without risking inaccuracies.)
When does daridorexant lose exclusivity and what is the generic entry risk?
Exclusivity concept that governs launch
Generic entry risk rises as:
- Patent listings expire, or
- Paragraph IV challenges succeed, or
- Settlements permit earlier launch
Market reality for insomnia
Insomnia products face:
- Strong brand loyalty and prescriber familiarity
- Ongoing safety monitoring requirements that can shift prescribing decisions
- Rapid formulary cycles once net pricing changes
Practical projection
Without verifiable patent expiration and Orange Book listing data in this run, no launch date can be stated.
What is the Orange Book status of daridorexant hydrochloride?
- Orange Book status controls whether ANDAs can be submitted and whether they trigger patent challenges.
- Orange Book-listed patents also predict the shape of generic entry barriers (composition, formulation, method, and use).
(This run does not include the Orange Book listing contents needed to provide an accurate table of listed patents and their expiration dates.)
What clinical trial expansions are most likely to increase revenue for daridorexant hydrochloride?
Most revenue-relevant label expansions
In insomnia DORA portfolios, revenue expansion is usually linked to:
- Broader adult insomnia subtypes under a single label frame
- Subpopulation targeting with higher insomnia prevalence and higher medical need
- Chronic insomnia persistence and long-term dosing evidence
- Real-world outcomes to support guideline adoption
Commercial impact pathway
Clinical updates increase market share when they:
- Strengthen the evidence line for prescribers
- Enable additional formulary categories
- Reduce insurer uncertainty in prior authorization
How strong is the patent and litigation posture for daridorexant hydrochloride?
- DORA litigation history in the category typically involves ANDA paragraph IV filings targeting composition/formulation or method-of-use patents.
- Settlement agreements frequently establish delayed launch windows and “carve-out” labels.
(This run does not include the paragraph IV and settlement datasets needed to identify cases, dockets, or settlement dates.)
Market analysis: what is the likely trajectory for daridorexant hydrochloride sales?
Market drivers
- Chronic insomnia prevalence and ongoing demand for non-benzodiazepine hypnotics
- Growth in DORA uptake among clinicians seeking alternatives to Z-drugs due to regulatory, safety, and payer constraints
- Persistent need for products with low next-day impairment profiles
Market headwinds
- Intensifying competition within DORAs, especially where payers negotiate aggressive rebates
- Segment-level demand shifts as competing hypnotics add new data or price advantage
- Budget impact in managed care: high-cost branded hypnotics often face formulary pressure
Projection framework (how to model)
A defensible sales projection typically decomposes into:
- Total addressable insomnia population treated
- DORA class adoption rate
- Within-class share for daridorexant driven by efficacy, safety perceptions, and net pricing
- Persistence and discontinuation over time
- Formulary access changes and prior authorization tightening or loosening
- Competitive product launches, dose expansions, and guideline updates
What typically dominates near-term outcomes
- Net price and rebate changes
- Coverage decisions (preferred vs non-preferred)
- Evidence communication around next-day impairment and safety in older adults
(No quantitative sales base or competitor market-share metrics are supplied in this run, so a numeric forecast cannot be produced without risking fabrication.)
Commercial scenario planning: how might daridorexant perform under different market conditions?
Scenario A: steady formulary access
- Result: continued share retention with modest growth aligned to class growth
- Key KPI: persistence and refill rates vs category
Scenario B: competitive rebate escalation
- Result: slower share growth or share erosion despite stable market demand
- Key KPI: net price erosion and prior authorization denials
Scenario C: label expansion or subgroup data improves adoption
- Result: faster uptake and improved prescriber confidence
- Key KPI: formulary expansion and lower time-to-PA approval
Scenario D: generic or biosimilar-like pressure (unlikely in DORA class short-term)
- Result: rapid share loss if entry occurs at meaningful price discounts
- Key KPI: immediate switching behavior and wholesaler ordering
Manufacturing and IP barriers: what risks exist for rivals attempting to launch?
- For oral small molecules, manufacturing barriers are usually less about scale and more about:
- Ability to maintain bioequivalence
- Formulation-specific IP constraints
- Compliance with FDA quality and stability standards
- Patent litigation and settlement-induced launch calendars
(A verified patent list and Orange Book claims are required for a specific barrier mapping.)
Key Takeaways
- Daridorexant hydrochloride remains a DORA option for adult insomnia with a clinical evidence base built around sleep onset and sleep maintenance endpoints and next-day tolerability.
- Near-to-mid term market performance will track DORA class growth, net pricing, and formulary dynamics more than “new” mechanism differentiation.
- Patent, Orange Book, and litigation specifics control generic entry risk, but this run does not include verified Orange Book listing and patent expiration data needed to state exact dates or case outcomes.
- The most revenue-relevant clinical trial updates are label-aligned expansions, chronic safety strengthening, and subgroup data that reduce payer uncertainty.
FAQs
- How do orexin receptor antagonists differ in next-day impairment risk in insomnia patients?
- What formulary criteria do payers use to prefer daridorexant over other DORAs?
- How do prior authorization and copay design affect daridorexant persistence and refill rates?
- What are the typical patent types that delay generic entry for insomnia small molecules?
- What endpoints in insomnia Phase 3 trials most influence guideline inclusion for DORAs?
References
- FDA. Drug Approval Package / Label information for Quviviq (daridorexant).
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Quviviq, daridorexant).
- ClinicalTrials.gov. Daridorexant hydrochloride (Quviviq) study records and results.
- USPTO / Google Patents. Patent documents for daridorexant (public record).
